TULSA: A newly formed Bermuda-based biotech run by former hedge fund partner Vivek Ramaswamy has struck a deal to in-license a shelved Alzheimer’s drug from GlaxoSmithKline ($GSK) with plans to put it into Phase III.
That late-stage study won’t start until the fourth quarter, but the newborn biotech isn’t waiting around at the starting line. The biotech, now operating as Axovant Sciences, has filed for a $172.5 million IPO, looking to cash in fast on the still-sizzling market for biotech stocks…